Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade-Reference-Cited by-同舟云学术

Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade

Published:2018-12-17 Issue:7737 Volume:565 Page:43-48
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Ishizuka Jeffrey J.,Manguso Robert T.,Cheruiyot Collins K.,Bi Kevin,Panda Arpit,Iracheta-Vellve Arvin,Miller Brian C.,Du Peter P.,Yates Kathleen B.,Dubrot Juan,Buchumenski Ilana,Comstock Dawn E.,Brown Flavian D.,Ayer Austin,Kohnle Ian C.,Pope Hans W.,Zimmer Margaret D.,Sen Debattama R.,Lane-Reticker Sarah K.,Robitschek Emily J.,Griffin Gabriel K.,Collins Natalie B.,Long Adrienne H.,Doench John G.,Kozono David,Levanon Erez Y.,Haining W. Nicholas

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41586-018-0768-9.pdf

Reference39 articles.

1. Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819–829 (2016).

2. Gao, J. et al. Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell 167, 397–404 (2016).

3. Yoshihama, S. et al. NLRC5/MHC class I transactivator is a target for immune evasion in cancer. Proc. Natl Acad. Sci. USA 113, 5999–6004 (2016).

4. Sade-Feldman, M. et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat. Commun. 8, 1136 (2017).

5. Manguso, R. T. et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature 547, 413–418 (2017).

Cited by 484 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Syndecan-1 inhibition promotes antitumor immune response and facilitates the efficacy of anti-PD1 checkpoint immunotherapy;Science Advances;2024-09-13

2. Small molecule innate immune modulators in cancer therapy;Frontiers in Immunology;2024-09-10

3. ADAR1 Promotes Invasion and Migration and Inhibits Ferroptosis via the FAK/AKT Pathway in Colorectal Cancer;Molecular Carcinogenesis;2024-09-06

4. Suppression of double-stranded RNA sensing in cancer: molecular mechanisms and therapeutic potential;Biochemical Society Transactions;2024-09-02

5. Innate immune sensing of cell death in disease and therapeutics;Nature Cell Biology;2024-09